Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 14/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12360008 | 1.00 | OPRD1 (0.67) | OPRD1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL12569762 | 0.92 | OPRD1 (0.62) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL84109 | 0.92 | OPRD1 (0.62) | OPRD1KCNH2OPRM1OPRK1 | |
| SCHEMBL12569769 | 0.88 | OPRD1 (0.60) | OPRD1OPRM1OPRK1 | |
| SCHEMBL84149 | 0.87 | OPRD1 (0.72) | OPRD1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL9925787 | 0.87 | OPRD1 (0.72) | OPRD1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL71180 | 0.86 | OPRD1 (0.71) | OPRD1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL29457724 | 0.86 | OPRD1 (0.71) | OPRD1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL71181 | 0.86 | OPRD1 (0.71) | OPRD1KCNH2OPRM1MEN1KMT2A | |
| SCHEMBL73453 | 0.86 | OPRD1 (0.71) | OPRD1KCNH2OPRM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207745-A1 | SOLID FORMS OF 4--N,N-DIETHYLBENZAMIDE, COMPOSITIONS THEREOF, AND USES THEREWITH | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | disclosed |
| US-20110207745-A1 | SOLID FORMS OF 4--N,N-DIETHYLBENZAMIDE, COMPOSITIONS THEREOF, AND USES THEREWITH | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | US | disclosed |
| WO-2011065905-A1 | SOLID FORMS OF 4-{(R)-(3-AMINOPHENYL)[4-(4-FLUOROBENZYL)-PIPERAZIN-1-YL]METHYL}-N,N-DIETHYLBENZAMIDE, COMPOSITIONS THEREOF, AND USES THEREWITH | ASTRAZENECA AB (SE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011065905-A1 | SOLID FORMS OF 4-{(R)-(3-AMINOPHENYL)[4-(4-FLUOROBENZYL)-PIPERAZIN-1-YL]METHYL}-N,N-DIETHYLBENZAMIDE, COMPOSITIONS THEREOF, AND USES THEREWITH | ASTRAZENECA AB (SE) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207745-A1 | SOLID FORMS OF 4--N,N-DIETHYLBENZAMIDE, COMPOSITIONS THEREOF, AND USES THEREWITH | VHL, TPMT, NNMT | OPRD1 4300/4885KCNH2 2033/4885OPRM1 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.